Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment

While an FDA advisory committee unanimously supported approval of the plaque psoriasis drug brodalumab, several recommended a black box warning on suicide risk that could limit sales of the drug.

Valeant Headquarters

The variety of strict safety recommendations from the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee could have the unintended consequence of limiting access to Valeant Pharmaceuticals International Inc.’s plaque psoriasis candidate Siliq (brodalumab), should it reach the market.

Although all 18 panelists recommended the treatment for approval, several said they would only support the FDA’s backing if the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip